Delta Lloyd Asset Management N.V. bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 15,697 shares of the life sciences company’s stock, valued at approximately $2,724,000.

Other hedge funds have also made changes to their positions in the company. Advisory Services Network LLC purchased a new position in Illumina during the 1st quarter worth $117,000. Penserra Capital Management LLC grew its stake in Illumina by 13.0% during the 2nd quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock worth $153,000 after buying an additional 102 shares during the last quarter. Paradigm Asset Management Co. LLC grew its stake in Illumina by 5.6% during the 2nd quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock worth $165,000 after buying an additional 50 shares during the last quarter. Patten Group Inc. lifted its position in Illumina by 2.7% during the 1st quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock worth $166,000 after acquiring an additional 25 shares during the period. Finally, NN Investment Partners Holdings N.V. lifted its position in Illumina by 11.3% during the 2nd quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock worth $171,000 after acquiring an additional 100 shares during the period. Hedge funds and other institutional investors own 93.34% of the company’s stock.

WARNING: “Delta Lloyd Asset Management N.V. Takes $2.72 Million Position in Illumina, Inc. (ILMN)” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://www.thecerbatgem.com/2017/09/04/delta-lloyd-asset-management-n-v-takes-2-72-million-position-in-illumina-inc-ilmn.html.

In other news, SVP Mostafa Ronaghi sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 2nd. The shares were sold at an average price of $195.00, for a total transaction of $1,950,000.00. Following the completion of the transaction, the senior vice president now directly owns 76,585 shares of the company’s stock, valued at approximately $14,934,075. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Omead Ostadan sold 1,672 shares of the firm’s stock in a transaction that occurred on Friday, July 7th. The stock was sold at an average price of $172.73, for a total transaction of $288,804.56. Following the transaction, the executive vice president now directly owns 26,242 shares of the company’s stock, valued at $4,532,780.66. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 165,806 shares of company stock valued at $30,551,242. Insiders own 1.60% of the company’s stock.

ILMN has been the subject of a number of research reports. Vetr cut Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 price target for the company. in a research report on Wednesday, May 31st. Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $195.00 price target for the company in a research report on Thursday, July 27th. Canaccord Genuity raised Illumina from a “hold” rating to a “buy” rating and lifted their price target for the stock from $170.00 to $215.00 in a research report on Monday, August 7th. First Analysis raised Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 price target for the company in a research report on Wednesday, August 2nd. Finally, Barclays PLC reaffirmed an “equal weight” rating and set a $150.00 price target on shares of Illumina in a research report on Wednesday, August 9th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $177.01.

Shares of Illumina, Inc. (NASDAQ ILMN) opened at 207.15 on Monday. The stock has a market capitalization of $30.24 billion, a price-to-earnings ratio of 41.56 and a beta of 0.81. Illumina, Inc. has a 1-year low of $119.37 and a 1-year high of $207.49. The firm’s 50-day moving average price is $187.91 and its 200 day moving average price is $177.34.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.68 by $0.14. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The company had revenue of $662 million during the quarter, compared to the consensus estimate of $642.38 million. During the same period last year, the firm earned $0.86 EPS. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. Equities research analysts expect that Illumina, Inc. will post $3.65 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.